Dianthus Therapeutics, Inc. $DNTH Stock Position Lifted by Glenmede Trust Co. NA

Glenmede Trust Co. NA raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 96.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,470 shares of the company’s stock after buying an additional 6,125 shares during the quarter. Glenmede Trust Co. NA’s holdings in Dianthus Therapeutics were worth $1,046,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DNTH. Vanguard Group Inc. increased its stake in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after acquiring an additional 406,254 shares during the last quarter. UBS Group AG boosted its position in Dianthus Therapeutics by 342.6% during the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after purchasing an additional 469,547 shares during the last quarter. SG Americas Securities LLC purchased a new position in Dianthus Therapeutics in the fourth quarter valued at about $765,000. BNP Paribas Financial Markets grew its stake in Dianthus Therapeutics by 1,275.3% in the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after purchasing an additional 441,156 shares in the last quarter. Finally, SummitTX Capital L.P. increased its position in Dianthus Therapeutics by 13.8% in the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after purchasing an additional 12,118 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Insider Transactions at Dianthus Therapeutics

In other news, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the transaction, the senior vice president directly owned 30,000 shares in the company, valued at approximately $2,424,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $362,480. This represents a 86.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 87,779 shares of company stock worth $7,985,235. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Trading Down 2.3%

NASDAQ DNTH opened at $109.92 on Friday. Dianthus Therapeutics, Inc. has a 1 year low of $18.08 and a 1 year high of $114.55. The company has a fifty day simple moving average of $94.40 and a 200 day simple moving average of $80.45. The company has a market cap of $6.01 billion, a P/E ratio of -26.49 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on DNTH shares. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush increased their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.